The invention relates to novel compounds having the general formula (I), and which compounds are useful to treat a disorder or disease characterized by bronchoconstriction, e.g. COPD and asthma.
NON-AQUEOUS ELECTROLYTE ADDITIVE, AND NON-AQUEOUS ELECTROLYTE FOR LITHIUM SECONDARY BATTERY COMPRISING THE SAME AND LITHIUM SECONDARY BATTERY
申请人:LG Chem, Ltd.
公开号:US20180198157A1
公开(公告)日:2018-07-12
The present invention relates to a non-aqueous electrolyte additive, and a non-aqueous electrolyte for a lithium secondary battery including the same and a lithium secondary battery, and particularly, to a non-aqueous electrolyte additive having a nitrile group and a propargyl group, and a non-aqueous electrolyte for a lithium secondary battery and a lithium secondary battery, which include the non-aqueous electrolyte additive so that capacity and cycle lifespan characteristics at high temperature can be improved.
[EN] HETEROCYCLIC WDR5 INHIBITORS AS ANTI-CANCER COMPOUNDS<br/>[FR] INHIBITEURS HÉTÉROCYCLIQUES DE WDR5 UTILISÉS EN TANT QUE COMPOSÉS ANTICANCÉREUX
申请人:NOVARTIS AG
公开号:WO2021026672A1
公开(公告)日:2021-02-18
Provided are compounds of Formula (I) and pharmaceutical acceptable salts thereof, which are inhibitors of WDR5. Also providing pharmaceutical compositions comprising such compounds, compositions comprising such compounds with an additional therapeutic agent and the therapeutic uses of such compounds.